Jeffrey L Browning

age ~73

from Brookline, MA

Get Report

Also known as:

Jeffery L Browning
Jeffery D Browning
Jeffery S Browning
Jeff Browning

Phone and address:: 32 Milton Rd APT 2, Brookline, MA 02445
6172323085

Connected to:

Jeffrey Browning Phones & Addresses

32 Milton Rd APT 2, Brookline, MA 02445 • 6172323085
Rockport, MA
Sibley, IL
Cambridge, MA
Gloucester, MA

Work

Company:

Chapman and Cutler LLP
Address:

Specialities

Asset Securitization • Banking • Commercial Lending and Real Estate • Business Law

Resumes

Jeffrey D Browning

view source

Jeffrey Browning

view source

Jeffrey Browning

view source

Marketing And Communications Associate At Habitat For Humanity Saint Louis

view source

Position:

Marketing and Communications Associate at Habitat for Humanity Saint Louis

Location:

Saint Louis, Missouri

Industry:

Marketing and Advertising

Work:

Habitat for Humanity Saint Louis since Apr 2013
Marketing and Communications Associate
Ansira Engagement Marketing Aug 2011 - Mar 2013
Account Representative I
Webster University Dec 2009 - Sep 2011
Student Supervisor of the Webter University Pool
Lutheran Senior Services - Lutheran Senior Services Jan 2011 - Aug 2011
Communications Intern
American Advertising Federation’s National Student Advertising Campaign (competition) Mar 2010 - Apr 2011
Account Executive of PR/ Media Planner/ Presenter

Education:

Webster University 2007 - 2011
BA, Advertising and Marketing Communications Webster University 2007 - 2011
Bachelor of Arts, Advertising and Marketing Communications

Skills:

Writing
Presenter
Microsoft Office
Basic Photoshop
InDesign
Basic Video Editing
Video Editing
Social Media
Advertising
Research
Event Planning

Interests:

Drawing/Painting Writing Sports - soccer, swimming Video Games Reading Movies

Honor & Awards:

2nd Place, 9th District 2011 - American Advertising Federation's National Student Advertising Competition

Lawyers & Attorneys

Jeffrey Browning - Lawyer

view source

Office:

Chapman and Cutler LLP

Specialties:

Asset Securitization
Banking
Commercial Lending and Real Estate
Business Law

ISLN:

915107016

Admitted:

2000

University:

University of California, Hastings College of the Law, San Francisco CA; University of Colorado, B.A., 1988; San Diego State University, M.B.A.

Law School:

University of California, Hastings College of the Law, JD - Juris Doctor, 2000

Medicine Doctors

Jeffrey D Browning

view source

Specialties:

Internal Medicine
Gastroenterology
Plastic Surgery within the Head & Neck

Education:

The University of Texas Southwestern (1998)

Isbn (Books And Publications)

John Register

view source

Author
Jeffrey Browning

ISBN #
0876856695

John Register

view source

Author
Jeffrey Browning

ISBN #
0876856709

Name / Title

Company / Classification

Phones & Addresses

Jeffrey A. Browning

THE BROWNING GROUP INC

Jeffrey A Browning

CQ HOLDINGS, LTD

Jeffrey Browning
Scientist

Grace Wong
Biotechnology Research

100 Arlington Rd, Boston, MA 02467

Jeffrey Browning

LITEHOUSE OF HERMITAGE, LLC

Us Patents

Soluble Lymphotoxin- Receptors As Therapeutic Agents For The Treatment Of Immunological Disease
view source
US Patent:

6403087, Jun 11, 2002
Filed:

Jun 8, 1998
Appl. No.:

09/000166
Inventors:

Jeffrey L. Browning - Brookline MA
Christopher D. Benjamin - Beverly MA
Paula S. Hochman - Newton MA
Assignee:

Biogen, Inc. - Cambridge MA
International Classification:

A61K 39395
US Classification:

4241341, 4241331, 514 2, 514 8, 5303871, 5303873
Abstract:

This invention relates to compositions and methods comprising âlymphotoxin- receptor blocking agentsâ, which block lymphotoxin- receptor signalling. Lymphotoxin- receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin- receptor extracellular domain that act as lymphotoxin- receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin- receptor or its ligand, surface lymphotoxin, that act as lymphotoxin- receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT- receptor signalling is provided.

Soluble Lymphotoxin- Receptor As A Therapeutic Agent For Treating Th-1 Cell-Associated Autoimmune Disease
view source
US Patent:

6669941, Dec 30, 2003
Filed:

Apr 30, 1999
Appl. No.:

09/303262
Inventors:

Jeffrey L. Browning - Brookline MA
Christopher D. Benjamin - Beverly MA
Paula S. Hochman - Brookline MA
Assignee:

Biogen, Inc. - Cambridge MA
International Classification:

A01N 3800
US Classification:

4241921, 514 2, 514 8, 514825, 514885, 514866, 514903
Abstract:

This invention relates to compositions and methods comprising âlymphotoxin- receptor blocking agentsâ, which block lymphotoxin- receptor signalling. Lymphotoxin- receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin- receptor extracellular domain that act as lymphotoxin- receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin- receptor or its ligand, surface lymphotoxin, that act as lymphotoxin- receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT- receptor signalling is provided.

Baff, Inhibitors Thereof And Their Use In The Modulation Of B-Cell Response
view source
US Patent:

6869605, Mar 22, 2005
Filed:

Jul 24, 2001
Appl. No.:

09/911777
Inventors:

Jeffrey Browning - Brookline MA, US
Christine Ambrose - Reading MA, US
Fabienne MacKay - Vaucluse, AU
Jurg Tschopp - Epalinges, CH
Pascal Schneider - Epalinges, CH
Assignee:

Biogen Idec Ma Inc. - Cambridge MA
International Classification:

A61A039/395
C07K016/44
US Classification:

4241411, 4241451, 4241771, 53038823, 5303892
Abstract:

The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.

Anti-Lymphotoxin-Beta Receptor Antibodies As Anti-Tumor Agents
view source
US Patent:

7001598, Feb 21, 2006
Filed:

Aug 16, 2001
Appl. No.:

09/931402
Inventors:

Jeffrey L. Browning - Brookline MA, US
Werner Meier - Burlington MA, US
Christopher D. Benjamin - Beverly MA, US
Assignee:

Biogen Idec MA Inc. - Cambridge MA
International Classification:

A61K 49/00
A61K 39/395
US Classification:

4241301, 4241431, 4241441
Abstract:

This invention relates to compositions and methods useful for treating or reducing the advancement, severity or effects of neoplasia by the administration of at least two or more lymphotoxin beta receptor (LT-β receptor) activating agents where at least one LT-β receptor activating agent is an anti-LT-β receptor antibody.

Lymphotoxin-Β, Lymphotoxin-Β Complexes, Pharmaceutical Preparations And Therapeutic Uses Thereof
view source
US Patent:

7030080, Apr 18, 2006
Filed:

Nov 7, 2001
Appl. No.:

10/040281
Inventors:

Jeffrey Browning - Brookline MA, US
Carl F. Ware - Riverside CA, US
Assignee:

Biogen, Inc. - Cambridge MA
University of California - Oakland CA
International Classification:

A61K 38/00
US Classification:

514 2, 4241431, 4241341, 514 8
Abstract:

This invention relates to lymphotoxin-β, a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23. D7 cells. This invention also relates to complexes formed between lymphotoxin-β and other peptides such as lymphotoxin-α and to complexes comprising multiple subunits of lymphotoxin-β. These proteins and complexes are useful in holding LT-α formed within the cell on the cell surface where the LT-α/LT-β complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-α/LT-β complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-β.

Treatment Of Follicular Lymphomas Using Inhibitors Of The Lt Pathway
view source
US Patent:

7060667, Jun 13, 2006
Filed:

Jul 26, 2000
Appl. No.:

09/626219
Inventors:

Jeffrey Browning - Brookline MA, US
Jeanette Thorbecke - Douglaston NY, US
Vincent Tsiagbe - New Rochelle NY, US
Assignee:

Biogen Idec MA, Inc. - Cambridge MA
New York University - New York NY
International Classification:

A61K 38/00
US Classification:

512 2
Abstract:

Therapeutic uses of inhibitors of the Lymphotoxin Pathway to treat tumors, specifically to treat follicular lymphomas.

Methods Of Treatment By Administering An Anti-Bcma Antibody
view source
US Patent:

7083785, Aug 1, 2006
Filed:

Feb 15, 2002
Appl. No.:

10/077438
Inventors:

Jeffrey Browning - Brookline MA, US
Christine Ambrose - Reading MA, US
Fabienne MacKay - Vaucluse, AU
Jurg Tschopp - Epalinges, CH
Pascal Schneider - Epalinges, CH
Jeffrey Thompson - Stoneham MA, US
Assignee:

Biogen Idcc MA Inc. - Cambridge MA
Apoxis SA - Epalingee
International Classification:

A61K 39/395
C07K 16/28
C12P 21/08
US Classification:

4241301, 4241331, 4241341, 4241411, 4241431, 4241731, 5303871, 5303873, 53038822, 514 12
Abstract:

A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

Antibodies Specifically Reactive With A Tumor Necrosis Factor Related Ligand
view source
US Patent:

7087725, Aug 8, 2006
Filed:

Oct 29, 2004
Appl. No.:

10/978131
Inventors:

Jeffrey Browning - Brookline MA, US
Yves Chicheportiche - Genev, CH
Assignee:

The Faculty of Medicine of the University of Geneva - Geneva
Biogen Idec MA Inc. - Cambridge MA
International Classification:

C12P 21/08
A61K 39/395
A61K 39/00
G01N 33/53
US Classification:

5303879, 5303873, 5303881, 4241331, 4241391, 4241411, 4241421, 436547, 436548
Abstract:

The present invention relates to Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.